ARS Pharmaceuticals (SPRY) EBIAT (2022 - 2025)
Historic EBIAT for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$51.2 million.
- ARS Pharmaceuticals' EBIAT fell 16741.43% to -$51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.0 million, marking a year-over-year decrease of 6300.1%. This contributed to the annual value of $8.0 million for FY2024, which is 11471.17% up from last year.
- ARS Pharmaceuticals' EBIAT amounted to -$51.2 million in Q3 2025, which was down 16741.43% from -$44.9 million recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' EBIAT registered a high of $49.9 million during Q4 2024, and its lowest value of -$51.2 million during Q3 2025.
- Moreover, its 4-year median value for EBIAT was -$14.4 million (2022), whereas its average is -$14.1 million.
- Its EBIAT has fluctuated over the past 5 years, first soared by 79662.39% in 2024, then tumbled by 25860.5% in 2025.
- Quarter analysis of 4 years shows ARS Pharmaceuticals' EBIAT stood at -$14.4 million in 2022, then surged by 50.32% to -$7.2 million in 2023, then surged by 796.62% to $49.9 million in 2024, then tumbled by 202.44% to -$51.2 million in 2025.
- Its last three reported values are -$51.2 million in Q3 2025, -$44.9 million for Q2 2025, and -$33.9 million during Q1 2025.